Clover Health (CLOV) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CLOV Clover Health

Watchlist

4.200
+0.080+1.94%

Close Nov 1 16:00 ET

4.210
+0.010+0.24%

Post 20:01 ET

2.09BMarket Cap-17500P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Earnings Preview: CLOV to Report Financial Results Post-market on November 06
Moomoo NewsOct 31 21:00 ET
Clover Health to Participate in Upcoming Investor Conferences
GlobeNewswireOct 29 16:05 ET
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
PR NewswireOct 28 18:30 ET
Here's Why We're Watching Clover Health Investments' (NASDAQ:CLOV) Cash Burn Situation
Yahoo FinanceOct 27 10:07 ET
How Is The Market Feeling About Clover Health Investments?
BenzingaOct 25 11:00 ET
Clover Health Investments, Corp. (NASDAQ:CLOV) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected
Simply Wall StOct 24 08:00 ET

Comments

Bellaah

Nov 1 11:51

$Clover Health (CLOV.US)$ 5 today

Blessed Dayz

Oct 25 05:51

$Clover Health (CLOV.US)$ Update
$Clover Health (CLOV.US)$ Centers for Medicare and Medicaid Services Increased the Star Rating of Its PPO Medicare Advantage Plans to 4 Stars for 2025. 8+

Blessed Dayz

Oct 25 03:40

$Clover Health (CLOV.US)$ This will be $6+ right after November 7 ..We tested around 5 this month after another good Earings/News this is Going to Run very smooth and healthy this is a real company with a great story line

10xStockPicks

Oct 24 07:55

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable

Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 million Americans take statin drugs, we see continued prescription growth & expect over 5...